Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Long-term data continue to bolster Trikafta’s dominant position in the cystic fibrosis market, says GlobalData

Positive long-term data for Trikafta, that was presented at the ATS 2026 International Conference, reinforces the therapy’s efficacy in adult cystic fibrosis (CF) patients with at least one F508del allele. The findings highlighted improvements in clinical and biochemical parameters, strengthening Trikafta’s leadership in the CF market and supporting informed patient monitoring and broader post-authorization market […]
Read more

FDA accelerated approval of Hepcludex to address serious unmet need in US HDV market, says GlobalData

The US Food and Drug Administration (FDA) has recently granted accelerated approval to Gilead Sciences’ antiviral, Hepcludex (bulevirtide-gmod), for the treatment of adults with chronic hepatitis delta virus (HDV) infection without cirrhosis or with compensated cirrhosis. Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone […]
Read more

ATS 2026: TETON-PPF study reinforces inhaled therapies potential in progressive pulmonary fibrosis, says GlobalData

Emerging Phase III evidence for inhaled treprostinil in progressive pulmonary fibrosis (PPF) is reinforcing industry expectations that combination therapy will shape the next phase of fibrotic lung disease treatment. TETON-PPF trial data presented at the 2026 American Thoracic Society (ATS) International Conference highlights the potential for inhaled therapies to complement existing antifibrotics, while intensifying competitive […]
Read more

ATS 2026: Jascayd reinforces combination therapy shift in US pulmonary fibrosis treatment, says GlobalData

New US subgroup data for Jascayd in idiopathic and progressive pulmonary fibrosis (IPF/PPF) is reinforcing the industry shift toward combination antifibrotic therapy in fibrotic lung disease management. Findings suggest the therapy can deliver meaningful clinical benefit alongside existing standard-of-care treatments, strengthening its commercial positioning as competitive intensity accelerates across the evolving pulmonary fibrosis treatment landscape, […]
Read more

Surveillance and prevention critical for Ebola control amid lack of effective prophylactics or therapeutics, says GlobalData

Following WHO reports of 53 confirmed cases, 600 suspected cases, and 139 suspected deaths from the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda; Anaelle Tannen, Senior Infectious Disease Analyst at GlobalData, a leading intelligence and productivity platform, offers her view: “On May 17, 2026, the WHO declared the Ebola […]
Read more

PABPC4 identification as key regulator of mitochondrial dysfunction signals potential for precision medicine in COPD, says GlobalData

A novel genetic mechanism underlying chronic obstructive pulmonary disease (COPD) is gaining attention, with new data identifying PABPC4 as a key regulator of mitochondrial function and emphysema pathogenesis. Early findings demonstrating the correction of a causal splicing defect using a first-in-class therapeutic approach signal potential for precision medicine in COPD, says GlobalData, a leading intelligence […]
Read more

Tariffs and geopolitical disruption reshape global pharma supply chains, says GlobalData

New US tariff measures and acute geopolitical tensions are reshaping the global pharmaceutical landscape, prompting companies to rethink supply chains and production strategies, says GlobalData, a leading intelligence and productivity platform. A key driver is the US administration’s decision to impose tariffs on imported pharmaceuticals and their ingredients, upending decades of medicines trade orthodoxy. The […]
Read more

First CAR-T therapy Satri-cel for solid tumors positions China at forefront of next oncology revolution, says GlobalData

Solid tumors are emerging as the next frontier for CAR-T innovation, with China poised to deliver the world’s first approved CAR-T therapy for gastric cancer. The anticipated approval signals a pivotal shift in oncology treatment, expanding CAR-T beyond hematological malignancies and intensifying competition in the rapidly evolving solid tumor landscape, where early clinical success, regulatory […]
Read more

Progressive pulmonary fibrosis market to reach $2.7 billion across 7MM by 2035, forecasts GlobalData

The progressive pulmonary fibrosis (PPF) market across the seven major markets (7MM*) is forecast to grow from $1.3 billion in 2025 to $2.7 billion in 2035 at a compound annual growth rate (CAGR) of 7.6%, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Progressive Pulmonary Fibrosis: Seven-Market Drug Forecast and Market […]
Read more

Meta-analysis backs broader use of blood pressure therapy in CKD, says GlobalData

Lowering blood pressure significantly reduces major cardiovascular events in chronic kidney disease (CKD) patients, with benefits matching those without CKD, according to a large meta-analysis. The findings challenge long-standing caution in advanced disease and support broader, earlier intervention. This evidence could reshape treatment strategies, expand antihypertensive use, and influence clinical guidelines across a growing, high-risk […]
Read more

Clinical trial recruitment remains key challenge in male infertility treatment, says GlobalData

Male infertility remains a difficult problem to treat, particularly because many patients and physicians prefer modern assisted reproductive technologies such as in vitro fertilization (IVF). A major reason for this difficulty is the limited clinical evidence and relatively sparse drug development focused on male-infertility therapies. Clinical data from randomized controlled trials (RCTs) is rare due […]
Read more

Auvelity provides breakthrough for treatment of Alzheimer’s agitation as first non-antipsychotic to be approved, says GlobalData

Following the news that the FDA has approved Axsome Therapeutics’ Auvelity (dextromethorphan + bupropion) for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD); Philippa Salter, Managing Neurology Analyst at GlobalData, a leading intelligence and productivity platform, offers her view: “A major unmet need in the AD market is for treatments for […]
Read more

Non-dopaminergic strategy gains ground as solengepras shows promise in early Parkinson’s, says GlobalData

Solengepras has showed early promise in addressing Parkinson’s disease’s (PD) overlooked non-motor burden, with Phase II data highlighting meaningful improvements in sleep and related symptoms despite limited motor gains. This reinforces a strategic shift beyond dopamine-centric care, signalling growing industry focus on holistic disease management, where targeting non-motor pathways could redefine treatment priorities and unlock […]
Read more

Non-GLP-1 innovation intensifies competition in booming global obesity market, says GlobalData

The global obesity drug market is diversifying rapidly as non-glucagon-like peptide-1 receptor (GLP-1R) therapies gain momentum, signaling a structural shift beyond incretin-led growth. While GLP-1R agonists continue to dominate revenues, emerging mechanisms, particularly calcitonin receptor–targeting drugs, are set to accelerate expansion from 2028, intensifying competition, broadening treatment pathways, and prompting leading companies to strategically hedge […]
Read more

Azetukalner’s phase III success holds potential to change treatment paradigm for focal onset seizures, says GlobalData

At the 2026 American Academy of Neurology (AAN) meeting, Xenon Pharmaceuticals announced positive results from the Phase III X-TOLE2 study of azetukalner, a novel, potent, KV7 potassium channel opener, in focal onset seizures (FOS). The study evaluated the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive, once-daily therapy taken with food for […]
Read more
1 2 3 4 … 108